The most common AEs (incidence of at least 5%) were reported in the label, such as upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (Genentech, 2020). The gene discussed is GPT; the disease is nasopharyngitis.